XCELLentis

XCELLentis was a Belgian biotechnology company focused on the development of advanced cell therapies for wound care and regenerative medicine. Founded as a spin-off from Ghent University and Innogenetics, the company leveraged expertise in keratinocyte biology to create treatments for chronic and acute wounds. Its primary product, Keracyte, utilized cultured skin cells to promote healing in conditions like venous leg ulcers and severe burns. The company established GMP-compliant manufacturing facilities in Ghent to support its clinical programs. In 2004, the company was acquired by the U.S.-based firm Dermal Therapeutics, integrating its European clinical progress into a broader dermatological portfolio.